GBA
Gemeinsamer
Bundesausschuss

Resolution

of the Federal Joint Committee on the Discontinuation of the Consultation Procedure under Section 35a paragraph 3b SGB V: MaaT013 (pooled allogeneic faecal microorganisms) (acute graft-versus-host disease); requirement of routine practice data collection and evaluations

of 5 November 2026

The Federal Joint Committee (GBA) decided the following at their session on 5 November 2026:

I. The consultation procedure on the requirement of routine practice data collection and evaluations according to Section 35a paragraph 3b SGB V for the active ingredient MaaT013 (pooled allogeneic faecal microorganisms) for the treatment of

"Adults with acute graft-versus-host disease (aGVHD) with gastrointestinal involvement following two prior therapies"

is discontinued.

II. The resolution will enter into force on the day of its publication on the GBA website on 5 November 2026.

The justification for this resolution will be published on the GBA website at www.g-ba.de.

Berlin, 5 November 2026

Federal Joint Committee
in accordance with Section 91 SGB V
The Chair

Dr Optendrenk

Courtesy translation – only the German version is legally binding.